Case report describes recurrent acute pancreatitis in a patient taking semaglutide, with both metabolic and idiopathic triggers identified, contributing to GLP-1 drug safety surveillance.
Pancreatitis warningRecurrent pancreatitis on semaglutide with metabolic triggers identified — reinforcing need for monitoring during rapid metabolic changes
What the researchers found
Recurrent acute pancreatitis in a semaglutide-treated patient involved both metabolic and idiopathic triggers, highlighting the importance of pancreatitis monitoring during GLP-1 therapy.
Why it matters
Pancreatitis can be life-threatening. As millions take semaglutide, understanding the circumstances that predispose to pancreatitis helps clinicians identify and protect high-risk patients.
The numbers in context
30-year-old patient. Three distinct episodes of acute pancreatitis.
How the study worked
Case report documenting recurrent pancreatitis episodes, clinical workup, temporal association with semaglutide, and identification of metabolic triggers.
Who was studied
30-year-old woman with T2DM, hypertriglyceridemia, and semaglutide use
What this study cannot tell us
Single case report. Pancreatitis has many causes, and semaglutide may be coincidental. Cannot determine incidence or establish definitive causation.
How to read the evidence
Preliminary evidence: single case report. Important for safety awareness but cannot establish risk frequency.
When this study was published
Published in 2025. Contributes to ongoing GLP-1 pancreatitis safety surveillance.
The bigger picture
The pancreatitis signal for GLP-1 drugs has been debated since their introduction. While large trials show a very small absolute risk, individual cases help identify risk factors (hypertriglyceridemia, rapid metabolic changes, alcohol, gallstones) that should trigger heightened monitoring.
Questions still open
- Should triglyceride levels be monitored more closely in GLP-1 drug users?
- Does rapid weight loss increase pancreatitis risk through metabolic changes?
- Which patients should avoid GLP-1 drugs due to pancreatitis risk?
Common questions
Can semaglutide cause pancreatitis?
Who is at higher risk for pancreatitis on GLP-1 drugs?
Read the original research
Idiopathic and Metabolic Triggers Leading to Recurrent Acute Pancreatitis in a 30-Year-Old Woman.
Hospital pharmacy, 60(4), 327-330
Citation
Ahmed, Fahamina; Chester, Taylor; Sarwar, Shaina. (2025). Idiopathic and Metabolic Triggers Leading to Recurrent Acute Pancreatitis in a 30-Year-Old Woman.. Hospital pharmacy, 60(4), 327-330. https://doi.org/10.1177/00185787251321072